<DOC>
	<DOCNO>NCT01725217</DOCNO>
	<brief_summary>To evaluate immune response safety follow single dose Novartis Meningococcal ACWY conjugate vaccine ( MenACWY-CRM ) healthy child , adolescent adult Russia .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal ACWY Conjugate Vaccine Healthy Children , Adolescents Adults Russia</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals eligible enrollment study : 1. Who gender , age 2 year time visit 1 , nature study describe : parent/legal representative provide write informed consent ( ≥2 &lt; 18 year age ) , provide write assent ( ≥11 &lt; 18 year age ) , provide write informed consent ( ≥18 year age onwards ) . 2. Who investigator believe subject and/or parent/legal representative could would comply requirement protocol ( e.g. , completion Diary Card , return followup visit ) . 3. Who good health determine medical history physical exam clinical judgment investigator 4. Who negative urine pregnancy test female subject 11 year age . Individuals eligible enrol study : 1. Who unwilling unable give write informed assent consent participate study . 2. Who perceive unreliable unavailable duration study period . 3. Who previous confirm suspected disease cause N meningitidis . 4. Who household contact and/or intimate exposure individual cultureproven N meningitidis infection within 60 day prior enrollment . 5. Who previously immunize meningococcal vaccine vaccine contain meningococcal antigen ( ) ( licensed investigational ) . 6. Who pregnant breast feeding ( female subject ) . 7. Who receive investigational nonregistered product ( drug vaccine ) within 28 day prior enrollment expect receive investigational drug vaccine prior completion study . 8. Who receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study plan receive vaccine within 30 day study vaccine . ( Exception : Influenza vaccine might administer 15 day prior study vaccination least 15 day study vaccination ) . 9. Who experience within 7 day prior enrollment significant acute infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( define body temperature ≥ 38°C ) within 3 day prior enrollment . 10. Who serious acute , chronic progressive disease ( e.g. , history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , Human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) , blood dyscrasia , sign cardiac renal failure severe malnutrition ) . Who epilepsy progressive neurological disease history GuillainBarre syndrome . 11. Who history anaphylaxis , serious vaccine reaction , allergy vaccine component include diphtheria toxin ( CRM197 ) latex syringe . 12. Who know suspected impairment/alteration immune function , either congenital acquire result ( example ) : receipt immunosuppressive therapy within 30 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose &gt; 1 mg/kg/day prednisone equivalent 30 day prior enrollment , cancer chemotherapy ) receipt immunostimulants receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study 13. Who know bleed diathesis , condition may associate prolonged bleeding time .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
	<keyword>MenACWY</keyword>
</DOC>